



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

information for conducting a meta-analysis. Our statement ‘no statistically significant associations were reported for prostate and pancreatic cancers’, which refers to cancer risk, is supported by summary estimates provided in the text and in Figure 3 (RR per 1 score 0.99, 95% CI 0.97–1.02; $I^2 = 0\%$, $P_{het} = 0.43$; six studies and 0.86, 95% CI 0.62–1.18; $I^2 = 90\%$, $P_{het} < 0.001$; two studies, respectively). Apart from lacking a dose–response relationship, the results for pancreatic cancer were only reported in two studies and were highly heterogeneous. Unfortunately, a meta-analysis was not possible for mortality data, because not enough studies assessed the relationship between meeting the 2007 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations and survival in patients with pancreatic or prostate cancer (Table 2B). As already stated in our discussion, upcoming studies using the recently updated WCRF/AICR score are warranted to draw firmer conclusions regarding mortality or cancer survival.² Concerning the comment regarding the use of relative risks (RRs), we used this term to uniformly refer to risk estimates [i.e. hazard ratio (HR), risk ratio, odds ratio (OR)] in tables and figures. In particular, all cohort studies provided results in HRs and only case–control studies used ORs. Thus, a primary meta-analysis synthesizing findings within the same study design does not have an issue of combining different measures of association. In addition, results for HR and OR were pooled to produce a summary estimate in the meta-analysis. This was done under the assumption that when events are rare and absolute cancer risks are small, these measures will be approximately equal in the studies.³

Finally, we assessed between-study heterogeneity and small-study effects using standard methods (Cochran’s Q, I^2 , Egger’s regression asymmetry test and funnel plot), and we appreciate the efforts of Jayaraj *et al.*¹ to complement our analysis with additional statistics that make our findings more transparent.

M. Solans^{1,2}, D. S. M. Chan³, P. Mitrou⁴, T. Norat³ & D. Romaguera^{5,6,7*}

¹CIBER Epidemiology and Public Health (CIBERESP), Madrid;

²Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain;

³Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London;

⁴World Cancer Research Fund International, London, UK;

⁵Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases, Palma de Mallorca;

⁶Barcelona Institute for Global Health (ISGlobal), Barcelona;

⁷CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain

(*E-mail: mariaadoracion.romaguera@ssib.es).

Available online 6 June 2020

© 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

<https://doi.org/10.1016/j.annonc.2020.05.029>

ACKNOWLEDGEMENTS

We thank Dr Kostas K Tsilidis, Imperial College London, for his thoughtful help preparing this response letter.

FUNDING

None declared.

DISCLOSURE

The authors have declared no conflicts of interest.

REFERENCES

- Jayaraj R, Kumaraswamy C, Raymond G, Baxi S, Shaw P. Conceptual and clinical interpretation of 2007 WCRF/AICR score in relation to cancer-related health outcomes. *Ann Oncol.* 2020;31(10):1413–1414.
- Shams-White MM, Brockton NT, Mitrou P, et al. Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention Recommendations: a standardized scoring system. *Nutrients.* 2019;11(7):1572.
- Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA.* 1998;280(19):1690–1691.

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2



Recently, Montopoli *et al.*¹ evaluated the relationship between androgen-deprivation therapy (ADT) for prostate cancer (PC) and risk of infection by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) through a population-based study of patients with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, Italy. They found that only four of 5273 PC patients treated with ADT (0.07%) developed SARS-CoV-2 infection and such patients had a significantly lower risk of SARS-CoV-2 infection than the patients who did not receive ADT.

To further investigate this potential relationship, we identified all of the cases of COVID-19 that have occurred in patients with metastatic castration-resistant PC and metastatic castration-sensitive PC treated in most of the high-volume referral medical oncology departments in northern Italy. Italy was the first country outside China to experience widespread SARS-CoV-2 infection and, as of 6 May 2020, the country with the fourth highest number of cases and deaths,² with the regions of northern Italy accounting for 80.4% of the cases and 86.7% of the deaths.³

The 19 high-volume medical oncology departments contributing to this study were treating a median of 80 patients with metastatic PC each (range 48–230), with a total of 1949. All of the patients were receiving ADT alone or in combination with one chemotherapeutic agent (docetaxel or cabazitaxel), one new-generation androgen-targeting agent (abiraterone or enzalutamide), or one radiopharmaceutical agent (radium 223). Thirty-six of these patients had a confirmed diagnosis of SARS-CoV-2 infection (1.8%). Their median age was 74.5 years,

and 66.7% were aged ≥ 70 years. Most of the infected patients (61.1%) were hospitalized; five are still infected, 20 (55.6%) have recovered, and 11 (30.6%) have died.

Our finding that the risk of developing a SARS-CoV-2 infection among patients with metastatic PC is higher than that described by Montopoli et al. may be due to differences in selection of the population considered to be potentially exposed to the infection. They evaluated a cohort of patients identified by means of a regional cancer registry, who may receive ADT for metastatic disease or biochemical relapse in the absence of any clinically detectable signs of disease, but the authors did not indicate which disease stage the patients were in when they were administered ADT. On the contrary, we identified a homogeneous population of consecutive patients with metastatic castration-sensitive PC/metastatic castration-resistant PC treated in most of the high-volume referral medical oncology departments in northern Italy. Clearly, all of our patients had advanced disease and this may explain the different incidence of SARS-CoV-2 infection.

In terms of lethality of SARS-CoV-2 infection, we observed three deaths among the 12 patients aged < 70 years (25%), a lethality rate that is higher than that expected in infected Italian males aged < 70 years as a whole ($< 13.0\%$). The eight deaths among the 24 patients aged ≥ 70 years (33.3%) lead to a lethality rate that is in line with that observed in Italian SARS-CoV-2-positive males aged ≥ 70 years as a whole ($> 30.3\%$).³ These findings do not apparently support the postulated protective effect of ADT, at least in patients with metastatic PC.

O. Caffo^{1*}, V. Zagonel², C. Baldessari³, A. Berruti⁴,
R. Bortolus⁵, S. Buti⁶, G. L. Ceresoli⁷, M. Donini⁸,
P. Ermacora⁹, G. Fornarini¹⁰, L. Fratino¹¹, C. Masini¹²,
F. Massari¹³, A. Mosca¹⁴, C. Mucciari¹⁵, G. Procopio¹⁶,
M. Tucci¹⁷, E. Verri¹⁸, P. Zucali¹⁹ & C. Buttigliero²⁰

¹Medical Oncology Department,
Santa Chiara Hospital, Trento;

²Department of Oncology, Oncology 1, Veneto Institute of
Oncology IOV-IRCCS, Padua;

³Medical Oncology Unit, University Hospital of Modena,
Modena;

⁴Medical Oncology Unit, University of Brescia at ASST
Spedali Civili, Brescia;

⁵Department of Radiation Oncology, Centro di Riferimento
Oncologico di Aviano CRO-IRCCS, Aviano;

⁶Medical Oncology Unit, University Hospital of Parma,
Parma;

⁷Thoracic and Urological Oncology Unit, Humanitas
Gavazzeni Clinic, Bergamo;

⁸Medical Oncology Department, ASST Cremona, Cremona;

⁹Oncology Department, University Hospital of Udine, Udine;

¹⁰Medical Oncology Department, IRCCS Azienda
Ospedaliera Universitaria San Martino-IST Istituto Nazionale
per la Ricerca sul Cancro, Genova;

¹¹Department of Medical Oncology, Centro di Riferimento
Oncologico di Aviano CRO-IRCCS, Aviano;

¹²Medical Oncology Unit, AUSL, IRCCS di Reggio Emilia,
Reggio Emilia;

¹³Division of Oncology, S. Orsola-Malpighi Hospital,
Bologna;

¹⁴Multidisciplinary Oncology Outpatient Clinic, Candiolo
Cancer Institute, FPO-IRCCS, Candiolo;

¹⁵Medical Oncology Department, Ramazzini Hospital, Carpi;

¹⁶Genito-Urinary Oncology Unit, Fondazione IRCCS Istituto
Nazionale Tumori of Milan, Milan;

¹⁷Medical Oncology Department, Cardinal Massaia
Hospital, Asti;

¹⁸Medical Oncology Division of Urogenital and Head & Neck
Tumours, IEO, European Institute of Oncology IRCCS, Milan;

¹⁹Department of Oncology,
Humanitas Clinical and Research Center, IRCCS, Rozzano,
Milan;

²⁰Medical Oncology Department, University of Torino, San
Luigi Hospital, Orbassano, Italy

(*E-mail: orazio.caffo@apss.tn.it).

Available online 18 June 2020

© 2020 European Society for Medical Oncology. Published
by Elsevier Ltd. All rights reserved.

<https://doi.org/10.1016/j.annonc.2020.06.005>

FUNDING

None declared.

DISCLOSURE

OC received honoraria as speaker or advisor for Astra Zeneca, Astellas, Janssen, Pfizer. VZ received honoraria as speaker or advisor for BMS, Merck, Bayer, Roche, Astellas, Servier, Astra Zeneca, Lilly. The other authors have no conflict of interest to be declared.

REFERENCES

- Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). *Ann Oncol*. 2020;31(8):1040–1045.
- Coronavirus (COVID-19) Disease Pandemic – Statistics & Facts. Statista 2020. Available at: <https://www.statista.com/topics/5994/the-coronavirus-disease-covid-19-outbreak/>. Accessed June 22, 2020.
- Epidemia COVID-19 – Aggiornamento Nazionale 2020. Available at: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_7-maggio-2020.pdf. Accessed June 22, 2020.